Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy.

MLA

Leverson, Joel D., et al. “Exploiting Selective BCL-2 Family Inhibitors to Dissect Cell Survival Dependencies and Define Improved Strategies for Cancer Therapy.” Science Translational Medicine, vol. 7, no. 279, Mar. 2015, p. 279ra40. EBSCOhost, https://doi.org/10.1126/scitranslmed.aaa4642.

APA

Leverson, J. D., Phillips, D. C., Mitten, M. J., Boghaert, E. R., Diaz, D., Tahir, S. K., Belmont, L. D., Nimmer, P., Xiao, Y., Ma, X. M., Lowes, K. N., Kovar, P., Chen, J., Jin, S., Smith, M., Xue, J., Zhang, H., Oleksijew, A., Magoc, T. J., … Souers, A. J. (2015). Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy. Science Translational Medicine, 7(279), 279ra40. https://doi.org/10.1126/scitranslmed.aaa4642

Chicago

Leverson, Joel D, Darren C Phillips, Michael J Mitten, Erwin R Boghaert, Dolores Diaz, Stephen K Tahir, Lisa D Belmont, et al. 2015. “Exploiting Selective BCL-2 Family Inhibitors to Dissect Cell Survival Dependencies and Define Improved Strategies for Cancer Therapy.” Science Translational Medicine 7 (279): 279ra40. doi:10.1126/scitranslmed.aaa4642.